If you’re a pediatric patient, or an adult under anesthesia, or unable to communicate for any other reason in the hospital, it’s very difficult for healthcare professionals to gauge how much pain medication you need.
That problem is now being solved by a novel Israeli technology that has received US Food and Drug Administration authorization for sales in the United States.
Medasense Biometrics, based in Ramat Gan, developed the groundbreaking NOL device for monitoring nociception (the physiological response to pain).
NOL’s unique multi-parametric sensor platform and advanced AI algorithms convert complicated data into a patient’s personal “signature of pain.”
“NOL technology has the potential to improve the lives of hundreds of millions of patients worldwide.”Galit Zuckerman-Stark, CEO of Medasense
The technology, currently utilized in operating rooms and other settings where patients are unable to communicate, enables clinicians to personalize pain management, control pain and avoid overmedication.
“NOL technology has the potential to improve the lives of hundreds of millions of patients worldwide, and we have already seen the impact it has had in multiple countries,” said Galit Zuckerman-Stark, CEO & founder of Medasense.
It is estimated that half of surgical patients suffer from moderate to severe postoperative pain and 12% suffer adverse events due to pain relief medication.These can result in extended hospitalization, additional healthcare costs, and a 50% increase in hospital readmissions.
NOL technology is currently distributed by the global med-tech leader Medtronic in Western Europe and Medasense has a distribution network in Canada, LATAM, Israel, and additional countries.
The company will now start seeking to raise funds to prepare for market access in the United States.
“Our mission is to help patients suffer less from pain and the adverse effects of pain medication. We are proud to offer the first and only measure of intraoperative pain in the US,” says Zuckerman-Stark.
Studies have shown that intraoperative NOL monitoring can reduce postoperative pain experienced by patients in the post-anesthesia care unit, and potentially reduce costs of care.